Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | -0.25% | 40.00 | 0.9% | $1281.75m | |
| JNJ | Johnson & Johnson | 0.14% | 170.19 | 0.7% | $1253.43m | |
| MRK | Merck & Co., Inc. | -0.60% | 78.22 | 0.7% | $926.88m | |
| ABBV | AbbVie, Inc. | -0.07% | 116.52 | 1.9% | $721.02m | |
| BMY | Bristol-Myers Squibb Co. | -0.31% | 64.84 | 1.0% | $719.56m | |
| LLY | Eli Lilly & Co. | 0.75% | 196.40 | 1.1% | $573.53m | |
| AZN | AstraZeneca Plc | 0.29% | 55.21 | 1.2% | $531.67m | |
| BTX | Brooklyn ImmunoTherapeutics, Inc. | -7.43% | 21.69 | 12.8% | $256.18m | |
| GSK | GlaxoSmithKline Plc | 1.11% | 39.09 | 0.2% | $191.43m | |
| NVS | Novartis AG | 0.68% | 89.00 | 0.2% | $173.64m | |
| VTRS | Viatris, Inc. | 0.44% | 16.00 | 0.0% | $168.43m | |
| CVAC | CureVac NV | 7.47% | 109.99 | 0.0% | $159.75m | |
| NVO | Novo Nordisk A/S | 0.28% | 79.11 | 0.1% | $72.19m | |
| SNY | Sanofi | 0.38% | 52.74 | 0.2% | $71.76m | |
| ATNX | Athenex, Inc. | 3.25% | 5.08 | 0.0% | $62.70m |
Company Profile
Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.